Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.

Authors :: Merseburger AS
Björk T
Whitehouse J
Meani D
Source :: Journal of comparative effectiveness research [J Comp Eff Res] 2015 Sep; Vol. 4 (5), pp. 447-53. Date of Electronic Publication: 2014 Dec 18.
Publication Year :: 2015
Abstract: Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings.<br />Patients & Methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant.<br />Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of €353,000 (EU5) and €699,000 (Sweden; 1-month formulations), and €259,000 (EU5) and €300,000 (Sweden; 3-month formulations).<br />Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used LHRH agonist preparations.

Subjects :: Drug Implants
Humans
Internationality
Male
Antineoplastic Agents, Hormonal economics
Antineoplastic Agents, Hormonal therapeutic use
Leuprolide economics
Leuprolide therapeutic use
Prostatic Neoplasms drug therapy
Prostatic Neoplasms economics

Full Text Access

Tools